P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF
P&G POSTS ONLY POINT-PLUS GAIN AS INDEX PLUNGES; ALL COMPONENTS OFF Procter & Gamble (up 1-3/4 to 49-3/8) was the only stock on the 52-issue "F-D-C" Index to gain more than a point as pharmaceutical/diversified stocks followed the market downward. Thompson Medical (up 3/4 to 22), Revlon (up 5/8 to 37-3/4) and Sterling (up 1/8 to 25-1/4) were the only other Diversified stocks to gain ground. Hardest hit were 2-1/8 point decliners Bergen-B (to 22-1/8) and Americal Hospital Supply (to 33-1/4). Overall, only nine of 52 stocks on the index broke even with two stocks unchanged on the week. Losing ground among Pharmaceuticals were Searle (off 5-1/4 to 37-1/2), Schering (down 2 to 35-1/2), and 1-1/2 point losers Lilly (to 61-1/8) and Bolar (to 27-3/8). All other movement on the component was fractional. Chart omitted.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth